Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

There is growing evidence that common variants of the transforming growth factor-beta (TGF-beta) signaling pathway may modify breast cancer risk. In vitro studies have shown that some variants increase TGF-beta signaling, whereas others have an opposite effect. We tested the hypothesis that a combined genetic assessment of two well-characterized variants may predict breast cancer risk. Consecutive patients (n = 660) with breast cancer from the Memorial Sloan-Kettering Cancer Center (New York, NY) and healthy females (n = 880) from New York City were genotyped for the hypomorphic TGFBR1*6A allele and for the TGFB1 T29C variant that results in increased TGF-beta circulating levels. Cases and controls were of similar ethnicity and geographic location. Thirty percent of cases were identified as high or low TGF-beta signalers based on TGFB1 and TGFBR1 genotypes. There was a significantly higher proportion of high signalers (TGFBR1/TGFBR1 and TGFB1*CC) among controls (21.6%) than cases (15.7%; P = 0.003). The odds ratio [OR; 95% confidence interval (95% CI)] for individuals with the lowest expected TGF-beta signaling level (TGFB1*TT or TGFB1*TC and TGFBR1*6A) was 1.69 (1.08-2.66) when compared with individuals with the highest expected TGF-signaling levels. Breast cancer risk incurred by low signalers was most pronounced among women after age 50 years (OR, 2.05; 95% CI, 1.01-4.16). TGFBR1*6A was associated with a significantly increased risk for breast cancer (OR, 1.46; 95% CI, 1.04-2.06), but the TGFB1*CC genotype was not associated with any appreciable risk (OR, 0.89; 95% CI, 0.63-1.21). TGFBR1*6A effect was most pronounced among women diagnosed after age 50 years (OR, 2.20; 95% CI, 1.25-3.87). This is the first study assessing the TGF-beta signaling pathway through two common and functionally relevant TGFBR1 and TGFB1 variants. This approach may predict breast cancer risk in a large subset of the population.

[1]  K. Matsuo,et al.  Transforming growth factor B1 T29C polymorphism and breast cancer risk in Japanese women , 2003, Breast cancer.

[2]  H. Hollema,et al.  Structural alterations of transforming growth factor‐β receptor genes in human cervical carcinoma , 1999, International journal of cancer.

[3]  R. Coffey,et al.  Mammary tumor suppression by transforming growth factor beta 1 transgene expression. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Ikeda,et al.  Association of a Polymorphism of the Transforming Growth Factor‐β1 Gene with Genetic Susceptibility to Osteoporosis in Postmenopausal Japanese Women , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[6]  E. Dmitrovsky,et al.  Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. , 1998, Cancer research.

[7]  R. Akhurst.  TGFβ signaling in health and disease , 2004, Nature Genetics.

[8]  E. Vlková,et al.  Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy. , 2002, American journal of medical genetics.

[9]  H. Ostrer,et al.  TβR-I(6A) Is a Candidate Tumor Susceptibility Allele , 1999 .

[10]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[11]  L. Sun,et al.  A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. , 1999, Cancer research.

[12]  B. Pasche.  Role of transforming growth factor beta in cancer , 2001, Journal of cellular physiology.

[13]  W. Weimar,et al.  TGF-β1 gene polymorphisms in patients with end-stage heart failure , 2001 .

[14]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[15]  R. Cardiff,et al.  Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Sporn,et al.  Transforming Growth Factor‐β , 1990 .

[17]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[18]  H. Beug,et al.  TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. , 1996, Genes & development.

[19]  X. Shu,et al.  Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. , 2004, Cancer research.

[20]  C. Arteaga,et al.  The multifunctional role of transforming growth factor (TGF)-ßs on mammary epithelial cell biology , 2005, Breast Cancer Research and Treatment.

[21]  A. Rademaker,et al.  TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  MitsuhiroYokota,et al.  Association of a T29→C Polymorphism of the Transforming Growth Factor-β1 Gene With Genetic Susceptibility to Myocardial Infarction in Japanese , 2000 .

[23]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[24]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[25]  A. Rademaker,et al.  TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  V. Sharma,et al.  Transforming growth factor-β1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage , 2000 .

[27]  M. Yokota,et al.  Association of a T29-->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. , 2000, Circulation.

[28]  J. Chang-Claude,et al.  A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .

[29]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[30]  B. Paulweber,et al.  The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. , 2003, Cancer letters.

[31]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[32]  E. Ziv,et al.  Association between the T29-->C polymorphism in the transforming growth factor beta1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. , 2001, JAMA.

[33]  M. Sporn,et al.  TGF-beta: problems and prospects. , 1990, Cell regulation.

[34]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[36]  H. Ostrer,et al.  TbetaR-I(6A) is a candidate tumor susceptibility allele. , 1999, Cancer research.

[37]  D. V. Berg,et al.  T 29 C Polymorphism in the Transforming Growth Factor B 1 Gene and Postmenopausal Breast Cancer Risk : The Multiethnic Cohort Study , 2004 .

[38]  D. Eccles,et al.  Transforming Growth Factor (cid:1) Receptor 1 Polyalanine Polymorphism and Exon 5 Mutation Analysis in Breast and Ovarian Cancer , 2022 .

[39]  M. Reiss,et al.  Transforming growth factor-β in breast cancer: A working hypothesis , 1997, Breast Cancer Research and Treatment.